Cell Line Development Market Set for Rapid Growth | Trend and Analysis, 2018-202
Posted by Pareesh on June 26th, 2018
Development of novel therapy to drive growth of the cell line development market
Cell line development has wide application areas. Development of immunotherapy for the treatment of cancer is major application of cell line development. According to the World Health Organization factsheet 2012, cancer is one of the leading cause of death from top three causes of non-communicable disease. Pharmaceutical and biotechnological companies are focusing on developing novel therapies such as immunotherapy due to its specificity and efficiency. Cell line development helps in speeding drug discovery process and optimization of clinical trials by providing high yield of monoclonal antibodies, which is expected to fuel growth of the cell line development market.
Increasing technological advancements in cell line development are expected to boost growth of the cell line development market. For instance, in November 2017, Lonza group launched Multiplex Cell line culture using GS Xceed Gene Expression System., which helps in testing multiple drug candidate at early developmental stage thereby saving four to six months, which otherwise is required in conventional development program.
North America to dominate the market for cell line development due to high investment in research by pharmaceutical companies to develop novel product
North America is expected to hold the dominant position in the global cell line development market, owing to high investment by pharmaceutical companies in developing a novel treatment product and increasing off patenting of major products, which would promote biosimilar drug development. Biosimilar drug having biological molecule needs to match in structure and composition with original product which needs cell line to confirm matching of structure and adhere to quality attribute such as glycoprofile, protein aggregation. For instance, according to 2016 report of International Trade Administration of Department of Commerce (USA), the U.S. generic drug sales reached an estimated US$ 70 billion in 2015, which represents quarter of the global market, due to a large number of drugs going off-patent and healthcare reforms favoring generics development. According to the same report, biologics account for over a third of all new drugs in clinical trials or which are waiting for FDA approval. According to Pharmaceutical Research and Manufacturers of America, companies such as Novartis AG, Merck and Company and F. Hoffmann-LA Roche AG in U.S. together invested in US$ 75 billion in research and development. Legal factors such Affordable Care Act which has already covered most of population would boost the usage for novel products as patients can get treated with insurance coverage without out of pocket expenditure on such medication.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1286
Collaborations by cell line development companies with drug discovery companies to speed up expansion of cell line development market
Some of the major players operating in the global cell line development market include Lonza Group AG, Sigma-Aldrich Corporation, Wuxi App Tec, Inc., American Type Culture Collection, Thermo Fisher Scientific, Inc., PX’Therapeutics SA., Selexis SA, GE Healthcare, European Collection of Cell Cultures , Corning, Inc., Sartorious AG, Goodwin Biotechnology Inc., and Cleancells. These companies are entering into strategic partnership with drug discovery companies to optimize their product development:
In December 2017, Selexis SA and Turgut Pharmaceuticals announced to enter into a third commercial license agreement, which would provide Turgut with access to Selexis SUREtechnology Platform and SURE CHO-M Cell Line for the development of biosimilar product for the treatment of two rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The companies were already in agreement (made in July 2016) to develop biosimilar products to treat inflammatory diseases and certain cancers using the SURE CHO-M Cell Lines.
Cell Line Development Market Taxonomy
On the basis of Product type: Reagents & Media, Equipment, On the basis of source: Mammalian, Non-Mammalian,. On the basis of cell line: Recombinant, Hybridomas, Continuous Cell Line, Primary Cell Line,.On the basis of application: Bioproduction, Drug Discovery, Toxicity Testing, Tissue Engineering, Research,. On the basis of end user: Pharmaceutical companies, Research and Academic Institution,.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Like it? Share it!
About the AuthorPareesh
Joined: May 31st, 2017
Articles Posted: 1,431
More by this author